A Critical Update on Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-cell Therapy

Large B-cell lymphomas (LBCLs) are one of the most common subtypes of non-Hodgkin lymphomas and while 1st-line standard of care has remained unchanged, the treatment paradigm has undergone a shift in recent years due to the development of novel therapeutic agents. These novel therapies include monoclonal antibody (mAb) therapies, mAb-conjugates, and chimeric antigen receptor (CAR)-T cell therapies.

Treatment of Large B-Cell Lymphoma: MOA and Clinical Efficacy Data of Novel Therapies

B-cell lymphomas consist of a heterogenous group of lymphoproliferative neoplasms originating from B-lymphocytes.  

Management of relapsed/refractory LBCLs remains a substantial and persistent clinical challenge, including optimal treatment sequencing, therapy evaluation and patient selection, and toxicity management.